HUPERZINE-A 250mg / 60 capsules

HUPERZINE-A 250mg/ capsule

Huperzine A is a natural compound that comes from the Huperzia serrata plant. It is often used in dietary supplements to support memory and brain health.

Huperzine supplementation affects:

1. Improved Memory: Huperzine A has been found to improve memory and cognition, especially in those with age-related memory decline.

2. Neuroprotective Effects: Huperzine A has been found to have neuroprotective effects, potentially reducing the risk of neurodegenerative diseases such as Alzheimer's disease.

3. Better Focus: Huperzine A has been found to improve focus and concentration, potentially reducing feelings of brain fogand improving productivity.

4. Increases Acetylcholine: Huperzine A is a potent, reversible, and specific inhibitor of the enzyme acetylcholine esterase (ACHE). This enzyme breaks down the major neurotransmitter acetylcholine, suggesting that some of the effects of Huperzine A may be due to generally elevated levels of acetylcholine in the brain.

5. Increases norepinephrine and dopamine levels – but not serotonin: According to one animal study, Huperzine A was found to increase norepinephrine and dopamine levels in the brains of rats without affecting serotonin

https://pubmed.ncbi.nlm.nih.gov/7500384/

According to one study, Huperzine A may work in a similar way to some Alzheimer's drugs that also affect the acetylcholine system in the brain, such as donepezil, rivastigmine, tacrine, and galanthamine - although with fewer side effects and slightly more favorable pharmacokinetics.

https://pubmed.ncbi.nlm.nih.gov/12895686/

A systematic review of various interventions for Alzheimer's disease used combined data from multiple studies to suggest that Huperzine A may have a statistically significant effect in reducing cognitive decline during Alzheimer's disease.

However, while early results are promising, there are some important limitations that should be noted. For example, the quality of these studies is slightly lower than the quality of studies of other medical interventions in Alzheimer's disease and other dementia-related conditions. Many such studies are poorly controlled or not designed to rule out author bias. Also, most studies and clinical trials came from China, which raises some questions about their overall validity.